Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune …
| Periodo | 2019-08 | 2019-08 | 2019-02 | 2019-02 |
|---|---|---|---|---|
| Real | — | — | — | — |
| Estimado | $-0.02 | $-0.02 | $-0.02 | $-0.02 |
| Sorpresa | — | — | — | — |
| Métrica | IMRN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 65.4% | 57.4% | +8.0% |
| Operating Margin | -73.3% | -34.4% | -39.0% |
| Net Margin | -71.6% | -32.5% | -39.1% |
| FCF Margin | — | -12.6% | — |
| ROE | -64.6% | -39.2% | -25.5% |
| ROA | -51.5% | -30.9% | -20.5% |
| Current Ratio | 5.09 | 2.73 | +2.36 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -51.5% | — |
| ✗Flujo de caja operativo positivo | −A$6M | −A$6M |
| ✗Rentabilidad sobre activos al alza | -51.5% | -44.6% |
| ✗Caja operativa/activos supera al ROA | -60.6% | ROA -51.5% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 5.09 | 5.46 |
| ✗Sin aumentar el nº de acciones | 231M | 228M |
| ✗Margen bruto al alza | 65.4% | 68.1% |
| ✓Rotación de activos al alza | 0.72 | 0.32 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -65.5% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 49.4% |
Immuron Ltd cotiza a 0.98 USD y tiene una capitalización bursátil de $8M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud